One-year follow-up of direct myocardial gene transfer of vascular endothelial growth factor-2 using naked plasmid deoxyribonucleic acid by way of thoracotomy in no-option patients.

[1]  C. Grines,et al.  Angiogenic Gene Therapy (AGENT) Trial in Patients With Stable Angina Pectoris , 2002, Circulation.

[2]  R. Hendel,et al.  Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease. , 2001, American heart journal.

[3]  J. Isner,et al.  Left Ventricular Electromechanical Mapping to Assess Efficacy of phVEGF165 Gene Transfer for Therapeutic Angiogenesis in Chronic Myocardial Ischemia , 2000, Circulation.

[4]  K. Endresen,et al.  Transmyocardial Revascularization Transmyocardial Revascularization With CO 2 Laser in Patients With Refractory Angina Pectoris Clinical Results from The Norwegian Randomized Trial , 2016 .

[5]  O. Frazier,et al.  Transmyocardial revascularization with a carbon dioxide laser in patients with end-stage coronary artery disease. , 1999, The New England journal of medicine.

[6]  Robert D. Dowling,et al.  Comparison of transmyocardial revascularization with medical therapy in patients with refractory angina. , 1999, The New England journal of medicine.

[7]  D. Burkhoff,et al.  Transmyocardial laser revascularisation compared with continued medical therapy for treatment of refractory angina pectoris: a prospective randomised trial , 1999, The Lancet.

[8]  J. Isner,et al.  Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. , 1999, The Annals of thoracic surgery.

[9]  L. Sharples,et al.  Transmyocardial laser revascularisation in patients with refractory angina: a randomised controlled trial , 1999, The Lancet.

[10]  J. Isner,et al.  Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. , 1998, Circulation.

[11]  J. Isner,et al.  Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia. , 1998, The American journal of pathology.

[12]  R. Jain,et al.  Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. , 1997, Science.

[13]  K. Alitalo,et al.  A novel vascular endothelial growth factor, VEGF‐C, is a ligand for the Flt4 (VEGFR‐3) and KDR (VEGFR‐2) receptor tyrosine kinases. , 1996, The EMBO journal.